| All | Training | Validation | Excluded | P* |
---|---|---|---|---|---|
n | 83 | 18 | 56 | 9 | Â |
Age at diagnosis, mean (SD) | 65 (12) | 64 (11) | 65 (13) | 72 (14) | 0.27 |
Sex, n (%) | Â | Â | Â | Â | 0.96 |
  Female | 43 (52) | 9 (50) | 27 (48) | 4 (44) |  |
  Male | 40 (48) | 9 (50) | 29 (52) | 5 (56) |  |
Ciliary body involvement, n (%) | Â | Â | Â | Â | 0.79 |
  Yes | 3 (4) | 1 (6) | 2 (4) | 0 (0) |  |
  No | 80 (96) | 17 (94) | 54 (969 | 9 (100) |  |
Tumor eye laterality, n (%) | Â | Â | Â | Â | 0.04 |
  Right | 49 (59) | 15 (83) | 28 (50) | 6 (67) |  |
  Left | 34 (41) | 3 (17) | 28 (50) | 3 (33) |  |
Extrascleral extension, n (%) | Â | Â | Â | Â | 0.78 |
  Yes | 1 (1) | 0 (0) | 1 (2) | 0 (0) |  |
  No | 82 (99) | 18 (100) | 55 (98) | 9 (100) |  |
Chief complaint at presentation, n (%) | Â | Â | Â | Â | 0.18 |
 Shadow in visual field | 10 (12) | 1 (6) | 8 (14) | 1 (11) |  |
 Reduced visual acuity | 19 (23) | 4 (22) | 12 (21) | 3 (33) |  |
 Pain | 1 (1) | 0 (0) | 0 (0) | 1 (11) |  |
 Floaters | 4 (5) | 1 (6) | 3 (5) | 0 (0) |  |
 Photopsia | 11 (13) | 4 (22) | 5 (9) | 2 (22) |  |
 No symptoms | 38 (46) | 8 (44) | 28 (50) | 2 (22) |  |
Visual acuity at diagnosis, mean LogMAR (SD) | 0.5 (0.3) | 0.5 (0.3) | 0.5 (0.3) | 0.6 (0.2) | 0.61 |
Tumor thickness at diagnosis, mean mm (SD) | 5.7 (2.6) | 5.2 (2.8) | 5.6 (2.5) | 6.6 (2.9) | 0.44 |
Tumor diameter at diagnosis, mean mm (SD) | 10.6 (2.4) | 11.0 (2.4) | 10.6 (2.4) | 11.0 (2.5) | 0.80 |
AJCC T-category at diagnosis, n (%) | Â | Â | Â | Â | 0.22 |
 T1a | 25 (30) | 8 (44) | 14 (25) | 3 (33) |  |
 T1b-d | 0 (0) | 0 (0) | 0 (0) | 0 (0) |  |
 T2a | 40 (48) | 6 (33) | 32 (57) | 2 (22) |  |
 T2b-d | 0 (0) | 0 (0) | 0 (0) | 0 (0) |  |
 T3a | 17 (21) | 4 (22) | 9 (16) | 4 (44) |  |
 T3b-d | 0 (0) | 0 (0) | 0 (0) | 0 (0) |  |
 T4a-c | 0 (0) | 0 (0) | 0 (0) | 0 (0) |  |
 T4e | 1 (1) | 0 (0) | 1 (2) | 0 (0) |  |
AJCC stage at diagnosis, n (%) | Â | Â | Â | Â | 0.22 |
 I | 25 (30) | 8 (44) | 14 (25) | 3 (33) |  |
 IIA | 40 (48) | 6 (33) | 32 (57) | 2 (22) |  |
 IIB | 17 (21) | 4 (22) | 9 (16) | 4 (44) |  |
 IIIA | 0 (0) | 0 (0) | 0 (0) | 0 (0) |  |
 IIIB | 0 (0) | 0 (0) | 0 (0) | 0 (0) |  |
 IIIC | 1 (1) | 0 (0) | 1 (2) | 0 (0) |  |
 IV | 0 (0) | 0 (0) | 0 (0) | 0 (0) |  |
Primary treatment, n (%) | Â | Â | Â | Â | 0.43 |
 Plaque brachytherapy | 71 (86) | 15 (83) | 47 (84) | 9 (100) |  |
 Enucleation | 12 (14) | 3 (17) | 9 (16) | 0 (0) |  |
Metastasis, n (%) | Â | Â | Â | Â | 0.16 |
 Yes | 22 (27) | 5 (28) | 17 (30) | 0 (0) |  |
 No | 61 (73) | 13 (72) | 39 (70) | 9 (100) |  |
Median follow-up for survivors, years (IQR) | 22.7 (0.7) | 22.6 (0.5) | 22.9 (0.7) | 22.4 (0.5) | 0.69 |